Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.5%. By the end of trading, Gilead rose $1.70 (2.9%) to $60.44 on average volume. Throughout the day, 8,224,319 shares of Gilead exchanged hands as compared to its average daily volume of 9,281,600 shares. The stock ranged in a price between $58.50-$61.04 after having opened the day at $58.83 as compared to the previous trading day's close of $58.74. Other companies within the Drugs industry that increased today were:

Astex Pharmaceuticals



), up 24.4%,

GW Pharmaceuticals PLC ADR



), up 17.6%,

Idera Pharmaceuticals



Scroll to Continue

TheStreet Recommends

), up 13.1% and




), up 10.7%.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $92.5 billion and is part of the health care sector. Shares are up 64.5% year to date as of the close of trading on Tuesday. Currently there are 19 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and increase in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front,

Rexahn Pharmaceuticals



), down 16.7%,

Prana Biotechnology



), down 12.5%,

Catalyst Pharmaceutical Partners



), down 12.4% and

Amicus Therapeutics



), down 6.8% , were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.